RWD

Premier, Inc. Announces Cross-Industry Initiative to Improve Diagnosis and Care for Chronic Kidney Disease

Retrieved on: 
Mercredi, mai 8, 2024
Technology, Hospitals, Diabetes, Health Technology, Practice Management, Health, Pharmaceutical, General Health, Artificial Intelligence, Conditional sentence, Acos, Organization, Hospital, National Kidney Foundation, Health equity, Group purchasing organization, Diagnosis, Uncover, Partnership, Conference, Artificial intelligence, Workflow, Pharmacy, Kidney disease, CKD, Science, Patient, RWD, Physician, Premier, Medical missions, Exhibition, PAS, Algorithm, AstraZeneca, Prevalence

Total inflation-adjusted Medicare expenditures for patients with end-stage renal disease increased to $53 billion in 2019.

Key Points: 
  • Total inflation-adjusted Medicare expenditures for patients with end-stage renal disease increased to $53 billion in 2019.
  • The partnership with AstraZeneca demonstrates a commitment to implement and learn about innovative approaches to driving optimization of guideline-directed medical therapy for patients.
  • PINC AI™ Stanson AI-powered technology, including clinical decision support and real-time alerts integrated into the provider workflow, to help strategically modify provider behavior to improve CKD screening, diagnosis and care quality.
  • For example, these resources could include the CKD Care Journey Roadmap, CKD Health Equity Primer, clinical decision support documentation (algorithms) and other digitized resources.

Lokavant Expands Team to Drive Strategic Direction of AI-Based Clinical Trial Feasibility Solution

Retrieved on: 
Mardi, mai 7, 2024
Technology, Clinical Trials, Professional Services, Biotechnology, Health, Data Analytics, Other Science, Science, Artificial Intelligence, University, Sonata, Public health, Drug development, AI, Microsoft Excel, GSK plc, Advisory board, Doctor of Philosophy, Pharmacy, Artificial intelligence, Data science, ChromeOS, Data, Patient, RWD, Noise, Medicine, Bristol Myers Squibb, Public health genomics, Clinical trial, Genomics, Therapy, Roivant Sciences, Pharmaceutical industry

The Lokavant Advisory Board brings together accomplished leaders in pharmaceutical research and development who are experts in global clinical trial operations.

Key Points: 
  • The Lokavant Advisory Board brings together accomplished leaders in pharmaceutical research and development who are experts in global clinical trial operations.
  • They work closely with the Lokavant leadership team, providing valuable insights into drivers for the evolving data and analytics needs of clinical trial sponsors and contract research organizations (CROs).
  • “I’m excited to work with Aaron and the new advisory team to incorporate their learnings into our clinical trial intelligence platform and study feasibility applications.
  • Together, we can drive efficiencies in trial operations while accelerating clinical research.”

Komodo Health & Partners Present 33 Real-World Evidence Research Studies at ISPOR 2024

Retrieved on: 
Lundi, mai 6, 2024
Technology, Health, Venture Capital, Professional Services, Artificial Intelligence, Oncology, Other Science, Mental Health, Research, Software, Health Technology, Science, COVID-19, Clinical Trials, Komodo, University of Washington, Lennox–Gastaut syndrome, FDA, Public, University, Target, International Society, RWE, Pregnancy, Policy, AI, Prevalence, Colorectal cancer, Myriad Genetics, LGS, Chronic inflammatory demyelinating polyneuropathy, Neutropenia, CRC, Conference, Workflow, REMS, Genetics, Schizophrenia, Takeda Pharmaceutical Company, Mental health, Neurology, RWD, MPH, Patient, Hypertension, Epilepsy, Gestational age, Standard of care, Stillbirth, Pharmacoeconomics, ZS, Merck, ZS Associates, Breast cancer, Mitigation, Pharmaceutical industry

Komodo Health today announced the publication of 33 new health economics and outcomes research (HEOR) studies using its Healthcare Map and AI-powered technology platform.

Key Points: 
  • Komodo Health today announced the publication of 33 new health economics and outcomes research (HEOR) studies using its Healthcare Map and AI-powered technology platform.
  • The studies, to be featured at the 2024 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Global Conference, shed light on important disease trends spanning women’s health, oncology, mental health, hypertension, neurology, and more.
  • Komodo Health researchers studied the differences in patient outcomes for pregnant women who continued or discontinued the use of antidepressants during pregnancy.
  • Komodo Health researchers analyzed whether the COVID-19 pandemic exacerbated inequities in breast cancer care through its impact on breast cancer staging and HCRU.

New Momentum in Pharma Automation: ArisGlobal's 2024 Industry Survey Report Highlights Surge in AI-Powered Safety & Regulatory Processes

Retrieved on: 
Mercredi, mai 8, 2024
Intelligent automation, Report, Automation, AI, Customer success, Regulation, Machine learning, Reality, Research, Artificial intelligence, SVP, RWD, Organization, Pharmaceutical industry

BOSTON, May 8, 2024 /PRNewswire/ -- ArisGlobal , an innovative life sciences technology company and creator of LifeSphere® , has unveiled a compelling trend among pharmaceutical organizations in its latest 2024 Industry Survey Report.

Key Points: 
  • BOSTON, May 8, 2024 /PRNewswire/ -- ArisGlobal , an innovative life sciences technology company and creator of LifeSphere® , has unveiled a compelling trend among pharmaceutical organizations in its latest 2024 Industry Survey Report.
  • The Report highlights a resolute commitment to embrace artificial intelligence (AI) to revolutionize their Safety and Regulatory process automation.
  • The international survey reveals that there is currently a pronounced gap between Life Sciences organizations' intentions and their actual use of next-generation technologies.
  • The full ArisGlobal 2024 Industry Survey Report, Life Sciences R&D Transformation: Ambitions for Intelligent Automation & Today's Reality, is available for download at

New Momentum in Pharma Automation: ArisGlobal's 2024 Industry Survey Report Highlights Surge in AI-Powered Safety & Regulatory Processes

Retrieved on: 
Mercredi, mai 8, 2024
Intelligent automation, Report, Automation, AI, Customer success, Regulation, Machine learning, Reality, Research, Artificial intelligence, SVP, RWD, Organization, Pharmaceutical industry

BOSTON, May 8, 2024 /PRNewswire/ -- ArisGlobal , an innovative life sciences technology company and creator of LifeSphere® , has unveiled a compelling trend among pharmaceutical organizations in its latest 2024 Industry Survey Report.

Key Points: 
  • BOSTON, May 8, 2024 /PRNewswire/ -- ArisGlobal , an innovative life sciences technology company and creator of LifeSphere® , has unveiled a compelling trend among pharmaceutical organizations in its latest 2024 Industry Survey Report.
  • The Report highlights a resolute commitment to embrace artificial intelligence (AI) to revolutionize their Safety and Regulatory process automation.
  • The international survey reveals that there is currently a pronounced gap between Life Sciences organizations' intentions and their actual use of next-generation technologies.
  • The full ArisGlobal 2024 Industry Survey Report, Life Sciences R&D Transformation: Ambitions for Intelligent Automation & Today's Reality, is available for download at

Deep 6 AI and Magnolia Market Access Partner to Accelerate Real-World Evidence (RWE) Projects for Life Sciences Companies and Healthcare Organizations

Retrieved on: 
Jeudi, mai 2, 2024
RWE, Ecosystem, Publication, Policy, EMR, Partnership, Magnolia, Research, Pathology, Artificial intelligence, Radiology, Patient, RWD, Magnolia Market, Clinical trial, Medical device

PASADENA, Calif., May 2, 2024 /PRNewswire/ -- Deep 6 AI, the leader in AI-powered patient recruitment and real-world data (RWD), together with Magnolia Market Access, a provider of tailored RWD insights and strategies for market access, health economics and outcomes research (HEOR), and healthcare policy, today announced a partnership to accelerate stakeholder decision-making across the pharmaceutical, biologic, and medical device product lifecycle. The combined RWE generation solution uses AI to develop fit-for-purpose, analysis-ready clinical data sets from electronic medical record (EMR) data months faster than traditional approaches.

Key Points: 
  • Typically, it can take life sciences companies a year or more to contract with healthcare organizations to gain access to EMR data.
  • "The speed and precision with which we generate clinical insights is paramount to our life sciences customers' success," said Amanda Forys, Managing Partner at Magnolia Market Access.
  • Life sciences companies can meet Deep 6 AI and Magnolia Market Access at ISPOR 2024 , May 5 to 8 in Atlanta, Georgia.
  • Contact Deep 6 AI or Magnolia Market Access to schedule a meeting.

ArisGlobal Helps Boehringer Ingelheim Transform Safety Signal Processing by Leveraging Latest LifeSphere Solutions

Retrieved on: 
Mercredi, mai 1, 2024
Boehringer Ingelheim, Safety, Risk management, Automation, Patient safety, Patient, RWD, Access, CIO, Generative

BOSTON, May 1, 2024 /PRNewswire/ -- ArisGlobal, a market leader in Life Sciences technology and the creator of LifeSphere®, announced today that research-driven global pharmaceutical company Boehringer Ingelheim is adopting the transformative new functionality of LifeSphere® Clarity™. 

Key Points: 
  • Boehringer Ingelheim's own patient safety teams created an on-premise advanced signal detection technology.
  • ArisGlobal acquired the technology in 2023, and has continued to develop the product, most notably transitioning the offering to the cloud under the name LifeSphere Clarity.
  • Dr. Robert Buchberger, Sr. VP Patient Safety and Pharmacovigilance at Boehringer Ingelheim, said, "We are very proud of the original signals innovation, developed in-house at Boehringer Ingelheim.
  • Clarity, as with the wider LifeSphere portfolio, helps biopharma companies expedite critical R&D processes and deliver more for patients, through advanced, efficient risk management."

ArisGlobal Helps Boehringer Ingelheim Transform Safety Signal Processing by Leveraging Latest LifeSphere Solutions

Retrieved on: 
Mercredi, mai 1, 2024
Boehringer Ingelheim, Safety, Risk management, Automation, Patient safety, Patient, RWD, Access, CIO, Generative

BOSTON, May 1, 2024 /PRNewswire/ -- ArisGlobal, a market leader in Life Sciences technology and the creator of LifeSphere®, announced today that research-driven global pharmaceutical company Boehringer Ingelheim is adopting the transformative new functionality of LifeSphere® Clarity™. 

Key Points: 
  • Boehringer Ingelheim's own patient safety teams created an on-premise advanced signal detection technology.
  • ArisGlobal acquired the technology in 2023, and has continued to develop the product, most notably transitioning the offering to the cloud under the name LifeSphere Clarity.
  • Dr. Robert Buchberger, Sr. VP Patient Safety and Pharmacovigilance at Boehringer Ingelheim, said, "We are very proud of the original signals innovation, developed in-house at Boehringer Ingelheim.
  • Clarity, as with the wider LifeSphere portfolio, helps biopharma companies expedite critical R&D processes and deliver more for patients, through advanced, efficient risk management."

Caris Life Sciences and COTA, Inc. Announce Collaboration to Expand Collective Multi-Modal Data Offering

Retrieved on: 
Mardi, avril 30, 2024
Sequence, Cancer, AUC, WTS, AI, Prognosis, RNA, MD, Partnership, Doctor of Philosophy, Research, DNA, Health information management, Data, Patient, Record, RWD, Health, WES, Biomarker, Medicine, Quality of life, COTA, Medical imaging

IRVING, Texas and NEW YORK, April 30, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, and COTA, Inc. (COTA), an oncology real-world data (RWD) and analytics company used by the world's leading pharmaceutical companies, today announced a collaboration to expand their multi-modal data offerings to support and accelerate biopharmaceutical drug development and patient care. 

Key Points: 
  • The combination of the breadth and depth of Caris' genomic, transcriptomic, proteomic and imaging data and COTA's high-quality curated clinical data that captures the treatment journeys and outcomes of cancer patients will result in a broad real-world, multi-modal data offering, at scale, to power the next wave of cancer therapeutics.
  • "Caris' partnership with COTA will enable biopharma to leverage a more complete dataset to power research and AI approaches for therapeutic development.
  • Caris was the first in the molecular diagnostic industry to provide Whole Exome Sequencing (WES) DNA coverage and Whole Transcriptome Sequencing (WTS) RNA coverage for every viable sample.
  • "By combining COTA's high-quality, curated data sourced from electronic health records with Caris' molecular data, life sciences researchers will be able to capture previously unseen insights to optimize cancer treatments that can improve a patient's prognosis and quality of life," said C.K.

Verana Health Announces Launch of Qdata® Thyroid Eye Disease

Retrieved on: 
Mercredi, avril 24, 2024
American Academy, Ophthalmology, Innovation, Research, Health information management, Data, Patient, RWD, Health, CAS, Quality of life, TED, SAN, Pharmaceutical industry

SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), today announced the launch of its Qdata® Thyroid Eye Disease (TED) module ahead of the Innovate TED Symposium in Napa, Calif. (April 26-28).

Key Points: 
  • SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), today announced the launch of its Qdata® Thyroid Eye Disease (TED) module ahead of the Innovate TED Symposium in Napa, Calif. (April 26-28).
  • Qdata TED is a meticulously curated dataset that encompasses RWD on more than 250,000 de-identified patients and provides information on extracting diagnoses from clinical notes in electronic health records.
  • “Thyroid Eye Disease is diagnosed in roughly 1 million Americans each year, and severely diminishes quality of life,” said Sujay Jadhav, CEO of Verana Health.
  • To learn more about Verana Health’s Ophthalmology Qdata modules, click here .